Navigation Links
Chemotherapy Induced Neutropenia (CIN) - Market Insights, Epidemiology and Market Forecast - 2023
Date:3/28/2017

NEW YORK, March 28, 2017 /PRNewswire/ -- "Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and global market trends of the Chemotherapy Induced Neutropenia for the seven major markets i.e., United States, Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE) and rest of the world (RoW).

The Report covers the therapeutics market revenue, treatment practice and Chemotherapy Induced Neutropenia (CIN) forecasted market share from 2017 to 2023 segmented by seven major markets. In addition, the report provides the historical and forecasted data of incident cases at risk of Chemotherapy Induced Neutropenia (CIN) in 10 cancer indications till 2023.

The report covers the number of patients for 10 cancer indications (i.e. Breast Cancer, Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Hodgkin's disease and Non-Hodgkin Lymphoma), who are at risk of developing CIN as an adverse event of the chemotherapies of respective cancers. Neupogen (Filgrastim), developed and marketed by Amgen is the first G-CSF approved for chemotherapy-induced neutropenia (CIN) in 1991.

Its PEGylated formulation, Neulasta was later approved in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute to majority of the market size, of CIN. However, New Chemical Entities are expected to launch in the near future. According to DelveInsight, the Global Market size of CIN in 2016 was USD 3.67 Billion.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Read the full report: http://www.reportlinker.com/p04800430-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/chemotherapy-induced-neutropenia-cin---market-insights-epidemiology-and-market-forecast---2023-300430694.html


'/>"/>
SOURCE Reportlinker
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Chemotherapy-induced Nausea and Vomiting Drugs Market Growth of 5.41%, 2017-2021 With GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck & Tesaro Dominating
2. BeyondSpring Presents Encouraging Clinical Data for Lead Asset on Chemotherapy-Induced Neutropenia at 2016 ASH Annual Meeting
3. Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy
4. Polaris Groups ADI-PEG 20 Shows Robust Clinical Activity in Malignant Plural Mesothelioma and NSCLC When Combined with Standard First Line Chemotherapy Regimen
5. DelMar Pharmaceuticals Presents Positive Data on the Benefit of VAL-083 in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC)
6. Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness in Childhood Cancer
7. CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers
8. CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium
9. Kaiser Permanente Study Finds Shingles Vaccine Remains Effective After Chemotherapy
10. Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
11. Acacia Pharma Initiates Phase II Study With APD403 in Chemotherapy Induced Nausea & Vomiting (CINV)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2019)... ... July 18, 2019 , ... NeoTract, a wholly owned ... of urology, today announced that Timothy Lesser, MD, Skyline Urology in Torrance, CA ... Dr. Lesser has achieved a high level of training and experience with the ...
(Date:7/18/2019)... ... July 18, 2019 , ... ComplianceLine, the ... 20 years, announced today it is moving into new corporate headquarters in Charlotte ... are thrilled to be moving into the new office which will allow our ...
(Date:7/17/2019)... ... 17, 2019 , ... Princeton, New Jersey – Supply Chain Wizard , ... been named a 2019 ‘Cool Vendor’ by Gartner, Inc. in Supply Chain Execution Technologies. ... we focused on two things. First, given the clear preferences of supply chain users, ...
Breaking Medicine Technology:
(Date:7/17/2019)... ... July 17, 2019 , ... ... plans participating in Medicare Advantage, Medicaid, and Marketplace programs is pleased to announce ... Electronic Health Records (EHR) integration at the point of care to ...
(Date:7/17/2019)... ... July 17, 2019 , ... Athena Software ... human services providers worldwide, has been awarded a California Multiple Award Schedules (CMAS) ... process for state and local government agencies in California by designating pre-approved suppliers ...
(Date:7/17/2019)... ... 17, 2019 , ... The Coalition of Medication-Assisted Treatment Providers ... of its member Opioid Treatment Programs (OTPs) at 12 locations are participating in ... (HCV) with the goal of achieving better outcomes through telemedicine. The study, “Comparison ...
(Date:7/13/2019)... ... July 14, 2019 , ... Dr. Rupa Jolly, dentist ... The New Orleans Advocate's A-List of Most Influential New Orleanians in 2019. She joins ... and other newsmakers that have made an impact on the New Orleans community. , ...
(Date:7/13/2019)... ... 12, 2019 , ... cbdMD, Inc., a nationally recognized consumer ... by Brightfield Group, a leading cannabis research firm. In their recent mid-year 2019 ... companies in two categories, Topicals and Skincare/Beauty. , "There is a massive shakeup ...
Breaking Medicine News(10 mins):